These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1857468)

  • 1. A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report.
    Hyodo T; Ono K; Koumi T; Miyagawa I; Okano T; Kagawa T; Hagino H; Kishimoto H; Oyama Y; Inoue A
    Nephron; 1991; 58(1):114-5. PubMed ID: 1857468
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormonal markers of early-stage osteitis fibrosa in patients on hemodialysis].
    Persichetti S; Sagliaschi G; Clemenzia G; Angelitti A; Gallo G; Maggi S; Ponzio R; Punzo G; Tozzo C
    Minerva Med; 1992 Nov; 83(11):721-4. PubMed ID: 1461543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 4. [Determination of bone mineral content and correlations with calciotropic hormones in periodic hemodialysis patients].
    Anelli F; De Maio P; Girardi V; Papagni S; Rossi G; Cantatore FP; Carrozzo M
    Minerva Urol Nefrol; 1992; 44(4):265-73. PubMed ID: 1299008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of terminal parathormone NH2 and COOH and plasma calcitonin in the blood of uremic patients under hemodialysis therapy].
    Di Landro D; Zanatta GP; Simioni N; Pinzani A; Zotti D; Perin N; Bertoli M; Naso A; Ruffatti A; Gasparotto ML
    Minerva Med; 1985 Mar; 76(9-10):419-23. PubMed ID: 3982699
    [No Abstract]   [Full Text] [Related]  

  • 6. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 7. A trial of calcitonin therapy in renal osteodystrophy.
    Delano BG; Baker R; Gardner B; Wallach S
    Nephron; 1973; 11(5):287-93. PubMed ID: 4753519
    [No Abstract]   [Full Text] [Related]  

  • 8. Propranolol and uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Rurale D; Belloli S; Aroldi A; Graziani G; Ponticelli C
    Proc Eur Dial Transplant Assoc; 1979; 16():668-71. PubMed ID: 549007
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy in dialyzed children.
    Baskin E; Beşbaş N; Saatçi U; Hasçelik G; Topaloğlu R; Ozen S; Bakkaloğlu A
    Turk J Pediatr; 2004; 46(1):28-31. PubMed ID: 15074371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy.
    Cundy T; Kanis JA
    Clin Chim Acta; 1987 May; 164(3):285-91. PubMed ID: 3297429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is calcitonin a helper of phosphate binders in the control of renal osteodystrophy?
    Ionova D; Zlatarska S; Kirjakov Z
    Nephrol Dial Transplant; 1995; 10(9):1782. PubMed ID: 8559512
    [No Abstract]   [Full Text] [Related]  

  • 12. [Calcitonin for therapy of renal osteodystrophy due to long-term hemodialysis in patients with chronic kidney failure].
    Ishida M; Yamada M
    Nihon Rinsho; 1991 Dec; 49 Suppl():725-31. PubMed ID: 1808343
    [No Abstract]   [Full Text] [Related]  

  • 13. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure].
    Weglarska J; Ziółkowska H; Pańczyk-Tomaszewska M; Sieniawska M
    Pediatr Pol; 1995 Dec; 70(12):1011-5. PubMed ID: 8649939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of serum bone Al-P isoenzyme and serum osteocalcin in patients on maintenance hemodialysis.
    Kaneko Y; Maruyama Y; Tunemi K; Hirata N; Nakatsuji F; Moriya A; Yoshida K; Motomiya Y; Ozono S; Hirao Y
    Nihon Jinzo Gakkai Shi; 1990 Mar; 32(3):345-51. PubMed ID: 2355668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteodystrophy of dialysed patients treated with vitamin D.
    Verberckmoes R; Bouillon R; Krempien B
    Proc Eur Dial Transplant Assoc; 1973; 10(0):217-26. PubMed ID: 4370246
    [No Abstract]   [Full Text] [Related]  

  • 18. Histological, hormonal, biochemical and radiological evaluation of vit. D therapy in osteodystrophy patients on RDT.
    Brancaccio D; Graziani G; Faccini JM; Banfi G; Pedoja G; Watson L
    J Urol Nephrol (Paris); 1976; 82(4-5):359-62. PubMed ID: 940182
    [No Abstract]   [Full Text] [Related]  

  • 19. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
    Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
    Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of renal osteodystrophy].
    Duursma SA; Dorhout Mees EJ
    Ned Tijdschr Geneeskd; 1978 Mar; 122(11):373-8. PubMed ID: 634388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.